FDA-Approved Osteoboost Device Shows Promise in Reducing Bone Density Loss in Post-Menopausal Women
The Osteoboost device, a wearable belt approved by the FDA in 2024, is designed to combat bone density loss in post-menopausal women diagnosed with osteopenia. The device delivers targeted vibrations to the spine and hips, mimicking the effects of exercise by stimulating bone-building cells called osteoblasts. A study involving 126 women over 50 showed that those using the device experienced significantly less bone strength loss in the spine over a year compared to a placebo group. Despite these promising results, some scientists have criticized the study's conclusions, arguing that the device's localized treatment may not be sufficient for a systemic condition like osteopenia. The device is available by prescription and costs about $1,000, as it is not covered by insurance. 
